Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.4.1389

Expression of DOG1, CD117 and PDGFRA in Gastrointestinal Stromal Tumors and Correlations with Clinicopathology  

Sun, Xiu-Wei (Department of Gastroenterology, the Third Affiliated Hospital of Harbin Medical University)
Feng, Zhan-Jun (Department of Gastroenterology, the Third Affiliated Hospital of Harbin Medical University)
Huang, Peng (Department of Gastroenterology, the Third Affiliated Hospital of Harbin Medical University)
Hao, Wang (Department of Gastroenterology, the Third Affiliated Hospital of Harbin Medical University)
Sui, Xing-Ling (Department of Gastroenterology, the Third Affiliated Hospital of Harbin Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.4, 2012 , pp. 1389-1393 More about this Journal
Abstract
Objective: To discuss the significance of DOG1, CD117 and PDGFRA in the diagnosis of gastrointestinal stromal tumors (GISTs), and analyze their correlations with clinicopathological features and risk ranking. Method: DOG1, CD117 and PDGFRA were detected with IHC Envision ldpe-g-nvp in 63 GISTs and 43 cases of non-GISTs, and analyzed for relations with clinicopathological factors (gender, age, location, tumor size, mitotic phase, histology) and risk degree. Results: The positive expression rate of DOG1, CD117 and PDGFRA in GISTs was 84.1% (53/63), 90.5% (57/63), 53.2% (33/63), respectively. Among the 6 CD117 negative cases, all were DOG1 positive and 5 were PDGFRA positive. Rates in patients with non-GISTs was 11.6%, 16.3%, 6.98%, respectively. Expression of DOG1 and PDGFRA demonstrated no significant variation with gender, age, position, tumor size, mitotic phase, histology, and risk rank. However, CD117 was related with position and histology (P=0.008 and P=0.045), those in the mesentery having a higher positive rate than those derived from stomach, small intestine, colon and rectum (50.0% vs 94.7%, P=0.008). Furthermore CD117 was also highly expressed in spindle and epithele types. Conclusions: DOG1 had a good sensitivity and specificity as a kind of newly discovered marker, especially for KIT negative GISTs. However, DOG1, CD117 and PDGFRA cannot be used for assessing the rish of patients.
Keywords
Gastrointestinal stromal tumor; KIT; PDGFR alpha; clinicopathological features; risk ranking;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Borquez Ma P, Neveu CR (2008). Gastrointestinal stromal tumors. An update. Rev Med Chil, 136, 921-9.
2 Caputo A, Caci E, Ferrera L, et al (2008). TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science, 322, 590-4.   DOI
3 Carles A, Millon R, Cromer A, et al (2006). Head and neck squamous cell carcinoma transcriptome analysis by comprehensive validated differential display. Oncogene, 25, 1821-31.   DOI
4 Corless CL, Heinrich MC (2008). Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol, 3, 557-86.   DOI
5 Dow N, Giblen G, Sobin LH, et al (2006). Gastrointestinal stromal tumors, differential Diagnosis. Semin Diagn Pathol, 23, 111-9.   DOI
6 Espinosa I, Lee CH, Kim MK, et al (2008). A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol, 32, 210-8.   DOI   ScienceOn
7 Heinrich MC, Corless CL, Duensing A, et al (2003). PDGFRA activating mutations in gastrointestinal stromal tumors. Science, 299, 708-10.   DOI   ScienceOn
8 Hornick JL, Fletcher CD (2002). Immunohistochemical staining for KIT(CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol, 117, 188-93.   DOI   ScienceOn
9 Joensuu H (2008). Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol, 39, 1411-9.   DOI
10 Kang YN, Jung HR, Hwang I (2010). Clinicopathological and immunohistochemical features of gastrointestinal stromal tumors. Cancer Res Treat, 42, 135-43.   DOI
11 Lopes LF, West RB, Bacchi LM, et al (2010). DOG1 for the diagnosis of gastrointestinal stromal tumor (GIST), Comparison between 2 different antibodies. Appl Immunohistochem Mol Morphol, 18, 333-7.   DOI
12 Medeiros F, Corless CL, Duensing A, et al (2004). KIT-negative gastrointestinal stromal tumors, proof of concept and therapeutic implications. Am J Surg Pathol, 28, 889-94.   DOI   ScienceOn
13 Miettinen M, Lasota J (2006). Gastrointestial stromal tumors, review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med, 130, 1466-78.
14 Miettinen M, Sobin LH, Lasota J (2005). Gastrointestinal stromal tumors of the stomach, a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol, 29, 52-68.   DOI   ScienceOn
15 Miettinen M, Wang ZF, Lasota J (2009). DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors, a study of 1840 cases. Am J Surg Pathol, 33, 1401-8.   DOI   ScienceOn
16 Miwa S, Nakajima T, Murai Y, et al (2008). Mutation assay of the novel gene DOG1 in gastrointestinal stromal tumors (GISTs). J Gastroenterol, 43, 531-7.   DOI   ScienceOn
17 Novelli M, Rossi S, Rodriguez-Justo M, et al (2010). DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology, 57, 259-70.   DOI
18 Pauls K, Merkelbach-Bruse S, Thal D, et al (2005). PDGFRalphaand c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features. Histopathology, 46, 166-75.   DOI   ScienceOn
19 Peterson MR, Piao Z, Weidner N, et al (2006). Strong PDGFRA positivity is seen in GISTs but not in other intra-abdominal mesenchymal tumors, Immunohistochemical and mutational analyses. Appl Immunohistochem Mol Morphol, 14, 390-6.   DOI
20 Rossi CR, Mocellin S, Mencarelli R, et al (2003). Gastrointestinal stromal tumors, from a surgical to a molecular approach. Int J Cancer, 107, 171-6.   DOI
21 Stamatakos M, Douzinas E, Stefanaki C, et al (2009). Gastrointestinal stromal tumor. World J Surg Oncol, 7, 61.   DOI
22 Rossi G, Valli R, Bertolini F, et al (2005). PDGFR expression in differential diagnosis between KIT-negative gastrointestinal stromal tumours and other primary soft-tissue tumours of gastrointestinal tract. Histopathology, 46, 522-31.   DOI
23 West RB, Corless CL, Chen X, et al (2004). The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors orrespective of KIT or PDGFRA mutations status. Am J Pathol, 165, 107-13.   DOI
24 Yang YD, Cho H, Koo JY, et al (2008). TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature, 455, 1210-5.   DOI